Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Travera Inc
Iovance Biotherapeutics, Inc.
AstraZeneca
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
ViroMissile, Inc.
MacroGenics
Immatics US, Inc.
Degron Therapeutics Co.
Transgene
HiFiBiO Therapeutics
Bayer
GlaxoSmithKline
HiFiBiO Therapeutics
Actym Therapeutics, Inc.
ImmVira Pharma Co. Ltd
Valo Therapeutics Oy
Guangzhou FineImmune Biotechnology Co., LTD.
Sensei Biotherapeutics, Inc.
Ascentage Pharma Group Inc.
Numab Therapeutics AG
Eli Lilly and Company
OncoC4, Inc.
Labcorp Corporation of America Holdings, Inc
BostonGene
Immunophotonics, Inc.
Agenus Inc.
Taproot Health
Immodulon Therapeutics Ltd
GI Innovation, Inc.
Rain Oncology Inc
Y-mAbs Therapeutics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Xencor, Inc.
Gene Surgery LLC
Cardinal Health 414, LLC
Innolake Biopharm
Presage Biosciences
Pfizer
DNAtrix, Inc.
BioEclipse Therapeutics
Adaptimmune
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
OncoResponse, Inc.
Hoffmann-La Roche
Genmab
Shanghai Yunying Medical Technology
Kineta Inc.